Navigation Links
BioMS Medical announces third quarter 2007 results
Date:11/14/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 14 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the third quarter, ended September 30, 2007.

"During the quarter, we continued to maintain momentum towards the commercialization of our lead drug, MBP8298, for the treatment of multiple sclerosis," said Kevin Giese, President and CEO of BioMS Medical.

Third Quarter 2007 Highlights:

- The independent Data Safety Monitoring Board (DSMB) for MINDSET-01,

the Company's on-going phase II trial of MBP8298 for relapsing-

remitting MS, completed a safety analysis and recommended that the

trial continue as per protocol. This double blind phase of this trial

is expected to complete in the second half of 2008.

- Subsequent to the end of the quarter,

- Two posters presented at the 23rd Congress of the European

Committee for Treatment and Research in Multiple Sclerosis

(ECTRIMS) in Prague, Czech Republic, in respect of the phase

III MAESTRO-01 secondary progressive MS (SPMS) study, showed

that over 70% of the screened patients had the drug's target

HLA DR2 and/or DR4 responder genes, and that an interim

analysis showed no significant safety concerns with the drug.

An interim safety and efficacy analysis for MAESTRO-01 is

planned for mid-2008.

- The Company announced that the U.S. pivotal phase III SPMS

trial, MAESTRO-03, is on track for full enrollment in 2008, and

completed enrollment of the first 133 patients who will form

the basis of an interim analysis that is expected in 2009.

Financial Results

The consolidated net loss for the three months ended
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
6. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
7. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
8. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
9. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
10. ATS Medical Expands Open Pivot Heart Valve Offerings
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... Calif. , May 27, 2015  Ceres, Inc. ... been awarded a U.S. patent for a genetic sequence ... areas such as research, product development and plant transformation. ... regulating key biosynthetic processes that are the target of ... other seed companies a commercial license to the innovation, ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 The ... with the Max Planck Society establishing the ... Photonics. The center will link two of the world's ... will be only the third Max Planck Centre in ... international society for optics and photonics, was with ...
(Date:5/26/2015)... and HILDEN, Germany , ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... QIAGEN Clinical Insight ® (QCI™) bioinformatics content ... interpret and report on genomic variants identified in ... for the bioinformatics platform are in oncology, for ...
(Date:5/26/2015)... Global Stem Cells Group ... the company’s first cellular and regenerative medicine symposium in ... day, hands-on stem cell training class Oct. 10. The ... M.D., President of Therapeutic Confrontations (CONFTERA) in Barcelona. ... in regenerative medicine and recent advances in cellular therapies, ...
Breaking Biology Technology:Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3
... how to make an exact cut on a metal rod. But ... carbon nanotube, with a diameter 1/50,000th the thickness of a human ... journal Proceedings of the Royal Society A , researchers at ... single-walled carbon nanotubes are cut, a finding that could lead to ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... previously announced public offering of 25,000,000 common shares of ... US $37,650,000. In connection with the offering, the Company ... up to 3,750,000 additional common shares to cover over-allotments, ...
... Dec. 17, 2010 InterMune, Inc. (Nasdaq: ... team to prepare for the commercialization of Esbriet™ (pirfenidone) ... received a positive CHMP opinion that is now awaiting ... Chairman, Chief Executive Officer and President of InterMune, said, ...
Cached Biology Technology:How do you cut a nanotube? Lots of compression 2YM BioSciences Closes Public Offering of Common Shares 2YM BioSciences Closes Public Offering of Common Shares 3InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 2InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 3InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 4InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 5InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 6
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/21/2015)... Canada , April 21, 2015 ... and evolving government policies are boosting access control systems ... According to a recently published report by ... Opportunities, 2020 ", the access control systems market in ... nearly USD1.2 billion by 2020.The access control systems market ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... 18.3.2013 In the fruit fly Drosophila , the functions ... intertwined - among other things they are involved in neurotransmitter ... of Biochemistry showed for the first time that flies cannot ... also raises new questions as to its function. Anna Ziegler, ...
... 18, 2013 Labrys Biologics Inc., a company focused on ... lead the development of RN-307, a Phase 2 ready anti-CGRP ... M.D., Ph.D., joins Labrys as chief medical officer, along with ... of project management; Michele Bronson , Ph.D., ...
... Researchers at Albert Einstein College of Medicine of Yeshiva ... found that macrophages white blood cells that play a key ... and eliminate the body,s red blood cells (RBCs). The findings could ... red blood cell production is thrown out of balance. The study, ...
Cached Biology News:Blind flies without recycling 2Blind flies without recycling 3Labrys Biologics Announces Key Executive Appointments 2Labrys Biologics Announces Key Executive Appointments 3Labrys Biologics Announces Key Executive Appointments 4White blood cells found to play key role in controlling red blood cell levels 2White blood cells found to play key role in controlling red blood cell levels 3
...
... BD PhosFlow Perm/Wash Buffer I can be ... signaling proteins to permeabilize cells and to ... wash buffer. Because saponin-mediated cell permeabilization is ... keep the cells in the presence of ...
... Mouse polyclonal antibody raised against ... Immunogen: PPP4C ... a.a) partial recombinant protein with ... Accession Number: NM_002720 ...
... Thermomixer R offers maximum application versatility ... heating, and cooling. Its active heating/cooling ... and temperature control ranges. Five different ... micro test tubes, are available for: ...
Biology Products: